Event to examine knowledge gaps and opportunities for robust scientific research into cannabinoid applications and their role in the evolving landscape.
TORONTO, March 5, 2019 /CNW/ – Avicanna Inc. (“Avicanna”), will host its second annual and first Canadian educational symposium, The Emergence of Biopharmaceutical Cannabinoids – From Research & Development to Clinical Translation, in Toronto on March 25, 2019. The exclusive, invitation-only event for Canadian and international clinical and research experts, industry experts and healthcare professionals, will be held at the MaRS Centre, the world’s largest innovation hub.1
The symposium will address opportunities as well as current gaps within “medical cannabis” research, including safety and toxicology concerns, as well as other challenges in the rapidly evolving industry.
The agenda will also cover recent and prominent developments in the biopharmaceutical cannabinoid research field, an overview of their role as active pharmaceutical ingredients, their challenges in formulation development and their potential role in several therapeutic areas.
Additionally, the event will also highlight Avicanna’s ongoing studies in a variety of therapeutic areas, including oncology, neurology, pain management and dermatology, which are being conducted in collaboration with a number of leading academic health science institutions in Canada and internationally.
“This event is a significant opportunity to educate and inform investigators, clinicians and industry experts on the evolving landscape of the basic science of cannabinoid research and its clinical applications, as well as the developing Canadian and international regulatory and industry environments. Furthermore, our goal is to be a catalyst in the exchange of information and drive collaboration among the communities involved in developing and delivering evidence-based cannabinoid solutions,” says Dr. Christine Allen, Avicanna’s Chief Scientific Office and Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto, and Symposium Chair.
The complete agenda can be viewed at: www.avicanna.com/symposium.
Avicanna is a Canadian biopharmaceutical corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna’s research and product development activities are primarily conducted out of Toronto, Canada including its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Torontoand the University of Toronto’s Faculty of Pharmacy. Avicanna’s scientists and researchers collaborate on the optimization and improvement of Avicanna’s products ranging from cosmetics to phyto-therapeutics to pharmaceutical preparations.
Avicanna’s vertically integrated and international operations also include its two majority owned cannabis cultivation subsidiaries Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia.
Avicanna’s research and development, and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
To learn more about Avicanna, please visit www.Avicanna.com.
SOURCE Avicanna Inc.
For further information: firstname.lastname@example.org.